Book a Meeting

Non-fucosylated Anti-Human Mesothelin (Amatuximab) Therapeutic Antibody (CAT#: BioBet-363ZP) Datasheet

Target
Mesothelin
Isotype
IgG1, κ
Description
ADCC-enhanced Amatuximab is a non-fucosylated anti-Mesothelin therapeutic biobetter antibody.
Indication
Pancreatic cancers
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Mesothelin antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
MSLN
Full Name
Mesothelin
Background
This gene encodes a preproprotein that is proteolytically processed to generate two protein products, megakaryocyte potentiating factor and mesothelin. Megakaryocyte potentiating factor functions as a cytokine that can stimulate colony formation of bone marrow megakaryocytes. Mesothelin is a glycosylphosphatidylinositol-anchored cell-surface protein that may function as a cell adhesion protein. This protein is overexpressed in epithelial mesotheliomas, ovarian cancers and in specific squamous cell carcinomas. Alternative splicing results in multiple transcript variants, at least one of which encodes an isoform that is proteolytically processed. [provided by RefSeq, Feb 2016]
Alternative Names
Amatuximab;931402-35-6;MORAb-009;Anti-mesothelin monoclonal antibody MORAb-009;MSLN;mesothelin;CAK1;MPF;CAK1 antigen;megakaryocyte potentiating factor;soluble MPF mesothelin related protein;pre-pro-megakaryocyte-potentiating factor;SMRP;
Gene ID
10232
UniProt ID
Q13421
Cellular Localization
Golgi apparatus, Extracellular region or secreted, Plasma membrane
Involvement in Disease
Diseases associated with MSLN include Mesothelioma, Malignant and Asbestosis.
Related Pathways
Its related pathways are Metabolism of proteins and Adhesion.
Function
Membrane-anchored forms may play a role in cellular adhesion. Megakaryocyte-potentiating factor (MPF) potentiates megakaryocyte colony formation in vitro.
Field of research
Cancer antibody; Controls and Markers antibody
Post-translational modifications
Both MPF and the cleaved form of mesothelin are N-glycosylated. Proteolytically cleaved by a furin-like convertase to generate megakaryocyte-potentiating factor (MPF), and the cleaved form of mesothelin.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
Amatuximab
Host
Chimeric
Species Reactivity
Human
Description
ADCC-enhanced Amatuximab is a non-fucosylated anti-Mesothelin therapeutic biobetter antibody.
Indication
Pancreatic cancers

Pancreatic cancers

Related Products

BetterBet™ Anti-Mesothelin Half-Life Extended Antibody (CAT#: AES-0622-ZP1000)
BetterBet™ Anti-Mesothelin FcγRIIB Binding Enhanced Antibody (CAT#: AES-0622-ZP344)
Highly Galactosylated Anti-Mesothelin (Amatuximab) Antibody (CAT#: BioBet-GA-363ZP)
BetterBet™ Anti-Mesothelin Recycling Antibody (CAT#: AES-0622-ZP16)
BetterBet™ Anti-Mesothelin On-Target Antibody (CAT#: AES-0622-ZP672)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany